Hormone Therapy May Up Heart Disease Risk During Gender Transition

Hormone therapy may contribute to increased risk for heart disease, such as heart attack, stroke, and blood clots during gender transition.

New study finds that patients receiving hormone therapy as part of their gender-transition treatment had an increased risk for cardiovascular events, including strokes, heart attacks, and blood clots. The findings of the study are published in the Circulation: Journal of the American Heart Association.

The results are based on analysis of medical records of 3,875 Dutch individuals who received hormone treatment between 1972and 2015 as part of their gender transition.

Hormone Replacement Therapy
Hormone Replacement Therapy can be likened to an ‘oasis in the desert’ for women in the throes of menopause.

‘Hormone therapy may contribute to increased risk for heart diseases during gender transition. A new study suggests to decrease the risk factors such as stopping smoking, exercising, eating a healthy diet and losing weight before starting therapy, and clinicians should remain to evaluate patients on an ongoing basis after that.’

"In light of our results, we urge both physicians and transgender individuals to be aware of this increased cardiovascular risk," said study author Nienke Nota, M.D., a researcher in the department of endocrinology at the Amsterdam University Medical Center.

"It may be helpful to reduce risk factors by stopping smoking, exercising, eating a healthy diet and losing weight, if needed before starting therapy, and clinicians should continue to evaluate patients on an ongoing basis thereafter."

Past research has shown that hormone therapy increases cardiovascular risk among people receiving it to alleviate symptoms of menopause, yet research evidence remains scarce on the effects of hormone treatment in people undergoing gender transition. Even though such individuals tend to be younger than menopausal patients receiving hormone-replacement therapy, transgender people may have more psychosocial stressors and other factors that increase cardiovascular risk, the researchers said.

Hormone Therapy for Migraine Offers No Risk of Heart Disease
Hormone therapy may be used in treating migraine without posing an increased risk of heart disease. It may also help prevent bone loss.

The analysis involved 2,517 transgender women, median age 30, who received estrogen, with or without androgen-suppressors, and 1,358 transgender men, median age 23, who received testosterone as part of their transition.

To gauge risk, the researchers determined the incidence of acute cardiovascular events heart attacks, strokes and deep vein thromboses (blood clots). They compared the incidence of such cases in the transgender population to that reported in the general population. Transwomen were followed for an average of 9 years since the start of hormone therapy, while transmen were followed for an average of 8 years after starting with hormones.

Hormone Therapy With Radiotherapy Improves Survival in Prostate Cancer
6 months of NADT and a relatively low dose of radiation can aid in efficient treatment of a large proportion of men with locally advanced prostate cancer

The analysis showed that transwomen individuals assigned male sex at birth but with female gender identity who were receiving hormones as part of their transition had more than twice as many strokes as women (29 versus 12) and nearly twice as many strokes as men (29 versus 16). There were five times as many deep-vein clots among transwomen (73) than women (13) and 4.5 times more than men (73 versus 16). Heart attacks occurred at more than twice the rate among transwomen (30) than women (13). Transmen those assigned female sex at birth but who had male gender identity and received hormones -- had a more than the three-fold elevation in heart-attack risk compared with women (11 versus 3).

The study was not designed to tease out the mechanism behind the increased risk. The researchers caution that their study was based solely on a review of medical records and could not account for risk factors such as smoking, psychosocial stressors, dietary and exercise habits. While those risk factors probably contribute to the increased cardiovascular risk, the researchers suggest that hormone therapy may contribute to increased risk as well.

Hormone Therapy In Prostate Cancer Ups Cardiac Death Risk In Men With A History Of Heart Disease
Hormone therapy for prostate cancer may up heart-related deaths in men with a prior history of heart disease.

In previous studies, it has been shown that triglyceride and insulin levels, for example, have both increased as a result of estrogen therapy and both are known to promote clogging and inflammation of the blood vessels. Additionally, estrogen therapy can render the blood more prone to clotting, which may explain the higher rate of strokes and blood clots observed in transwomen, the authors said. The rise in heart attack risk found in transmen receiving testosterone may be explained partly by the hormone's tendency to make the blood stickier by increasing the concentration of red blood cells along with lowering the level of good cholesterol and raising the level of bad cholesterol, the research team said.

Source-Eurekalert